Vlasveld L T, Beijnen J H, Sein J J, Rankin E M, Melief C J, Hekman A
Department of Immunology, The Netherlands Cancer Institute, Amsterdam.
Eur J Cancer. 1993;29A(14):1977-9. doi: 10.1016/0959-8049(93)90456-p.
In a previous clinical study using a continuous infusion schedule of recombinant interleukin-2 (rIL-2) we noted a nearly complete loss of activity of EuroCetus rIL-2 when dissolved in 10 ml saline and infused at a very low rate through a plastic infusion device. In the present study, we demonstrated that the loss resulted from a concentration-dependent precipitation of rIL-2 in saline and adherence of the protein to the tubing material. These phenomena were not noted for four other rIL-2 muteins tested [Glaxo, Hoffmann-LaRoche, Amgen (2 muteins)]. EuroCetus rIL-2 was found to be completely soluble in water and 5% glucose.
在先前一项使用重组白细胞介素-2（rIL-2）持续输注方案的临床研究中，我们注意到，当将EuroCetus公司生产的rIL-2溶解于10毫升生理盐水中并通过塑料输液装置以极低速率输注时，其活性几乎完全丧失。在本研究中，我们证明，这种活性丧失是由于rIL-2在盐水中的浓度依赖性沉淀以及蛋白质与管材的黏附所致。对于所测试的其他四种rIL-2突变体[葛兰素史克公司、霍夫曼-罗氏公司、安进公司（两种突变体）]，未观察到这些现象。发现EuroCetus公司生产的rIL-2完全可溶于水和5%葡萄糖溶液。
